Biotech

AffaMed Therapeutics Announces New Drug Application Acceptance by Singapore Health Sciences Authority (HSA) for DEXTENZA® for Treatment of Ocular Inflammation and Pain Following Ophthalmic Surgery, and Ocular Itching Associated with Allergic Conjunctivitis

2024-02-19 09:00 3052

SHANGHAI, Feb. 19, 2024 /PRNewswire/ -- AffaMed Therapeutics ("AffaMed"), a biotechnology company dedicated to developing and commercializing transformative pharmaceutical, and surgical products that address critical unmet medical needs in ophthalmology, today announced that the Singapore Health ...

Pharus Diagnostics Signs Worldwide Exclusive License Agreement with City of Hope for Novel Biomarkers to Be Used in Liquid Biopsy Screening for Early Pancreatic Cancer Diagnosis

2024-02-15 16:05 1713

LOS ANGELES, Feb. 15, 2024 /PRNewswire/ -- Pharus Diagnostics ("PharusDx") today announced a global exclusive license agreement with City of Hope cancer center for proprietary biomarkers to be used in early screening of individuals at risk for pancreatic ductal adenocarcinoma (PDAC). This license...

iNtRON, Development of PHAGERIA® Anti-Cancer Candidate with Enhanced Antimicrobial Activity by Robot Bacteriophage platform technology

2024-02-15 11:37 1304

▶ Robot Bacteriophage against microbiome associated with colorectal cancer ▶ Bacteriophage Improvement Platform technology with a broad antimicrobial activity ▶ Proprietary Technology incorporating CRISPR/Cas Technology BOSTON, Feb. 14, 2024 /PRNewswire/ -- iNtRON Biotechnology ("iNtRON", www.i...

YS Biopharma Announces Appointment of New Directors

2024-02-14 20:50 3396

GAITHERSBURG, Md., Feb. 14, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd. (Nasdaq: YS) ("YS Biopharma" or the "Company", and together with its subsidiaries, "YS Group"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccin...

Brii Biosciences Announces Agreement to Acquire VBI's IP Rights in BRII-179 (VBI-2601) and Plans to Initiate Technology Transfer to Expand Clinical and Commercial Supplies

2024-02-14 08:07 3594

Acquiring all intellectual properties relating to BRII-179 and eliminating future milestone and royalty payments to VBI, subject to achievement of certain activities Transferring manufacturing technologies of BRII-179 and PreHevbrio/PreHevbri to additional manufacturing sites and expanding footp...

Delta Thailand Wins Prime Minister's Best Industry Award and MIND Ambassador Award 2023 for Outstanding Contributions

2024-02-13 16:37 1849

BANGKOK, Feb. 13, 2024 /PRNewswire/ -- Delta Electronics (Thailand) PCL. received the Prime Minister's Best Industry Award 2023, which is the highest honor above all other Prime Minister's Industry Award categories given to only one select company each year. In addition, Delta received the MIND A...

BioVaxys Acquires All Intellectual Property, Immunotherapeutics Platform Technology, and Clinical Stage Assets of the Former IMV Inc.

2024-02-13 03:26 3739

VANCOUVER, BC, Feb. 13, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company") announced that it has executed the definitive  Asset Purchase Agreement datedFebruary 11th, 2024 to acquire the entire portfolio of discovery, preclinical and cli...

UFC WORLD CHAMPION JON JONES, LIFECYKEL LABS, CANTERBURY-BANKSTOWN BULLDOGS AND BETTER BREATHING DEVICES HOST ELITE PERFORMANCE/TRAINING DAY

2024-02-09 18:09 3033

SYDNEY, Feb. 9, 2024 /PRNewswire/ -- Jon Jones, UFC world champion and arguably the best MMA fighter to have ever existed is touringAustralia and has teamed up with Lifecykel Labs to host and facilitate a best-in-class performance training day which was held at the Canterbury-Bankstown Bulldogs h...

Biocon Biologics Partners with Sandoz Australia for Biosimilars Trastuzumab and Bevacizumab

2024-02-09 11:22 2237

BENGALURU, India, Feb. 9, 2024 /PRNewswire/ -- Biocon Biologics Ltd (BBL), a fully integrated biosimilars company and subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), today announced a five-year partnership with Sandoz AG ('Sandoz') which provides Sandoz the exclusive rights to promote, ...

Cathay Biotech and 3P.COM Signed Joint Venture Agreement to Propel Sustainable Composite Innovations

2024-02-08 23:00 1615

China's Cathay Biotech Inc. and South Korea's 3P.COM Co. Limited signed an agreement to establish a joint venture, targeting the development of bio-based polyamide thermoplastic composites.  SHANGHAI, Feb. 8, 2024 /PRNewswire/ -- Cathay Biotech Inc. ("Cathay") and 3P.COM Co. Limited ("3P.COM") s...

MGI Named a Finalist in the 2024 Edison Awards™ for Innovative DNBSEQ-T20x2* Gene Sequencer

2024-02-08 21:00 1458

SHENZHEN, China, Feb. 8, 2024 /PRNewswire/ -- MGI Tech , a company committed to building core tools and technology to lead life science, today announced its nomination as a finalist for the2024 Edison Awards™  in the "Health, Medical ...

Tianlong's New Launch Gentier X3 Made its Appearance at Medlab Middle East 2024

2024-02-08 21:00 2703

DUBAI, UAE, Feb. 8, 2024 /PRNewswire/ -- The 4-day Medlab Middle East 2024 at the Dubai World Trade Center came to an end successfully onFebruary 8. MedLab is the largest exhibition of medical equipment in theMiddle East region, attracting visitors worldwide to experience the academic atmosphere ...

I-Mab Signs Agreement to Divest its Assets and Business Operations in China

2024-02-07 19:00 1267

* Agreement marks an important milestone to advance the Company's intent to become a U.S.-based biotech  * Agreement provides for a strategic focus in advancing I-Mab's potential of differentiated oncology clinical assets and builds shareholder value by streamlining the operating model, reduc...

NouvNeu001 Achieves Milestone with Successful Dosing of First Patient, Signaling Smooth Progress in iRegene Therapeutics' Multicenter Clinical Trial for Innovative Novel Parkinson's Disease Therapy

2024-02-05 21:00 1409

WUHAN, China, Feb. 5, 2024 /PRNewswire/ -- iRegene Therapeutics Co., Ltd (iRegene) recently announced that NouvNeu001, the company's first innovative product, has completed the dosing for its first patient at Beijing Hospital, and the patient has also successfully concluded the observation period...

Innovent Announces Retirement of CFO and Appointment of New CFO

2024-02-05 16:45 2411

ROCKVILLE, Md. and SUZHOU, China, Feb. 5, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("c") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and other ...

Agilis Robotics Unveils Groundbreaking Advancements in Endoluminal Surgery

2024-02-05 09:53 1484

HONG KONG, Feb. 2, 2024 /PRNewswire/ -- Agilis Robotics, a leading innovator in surgical robotics, is spearheading a paradigm shift in the field of "incisionless" endoluminal surgery. The company has made remarkable technological breakthroughs in developing highly miniaturized and flexible robot...

Acepodia Announces FDA Clearance of Investigational New Drug Application for ACE2016, a First-in-Class Allogeneic Anti-EGFR Cell Therapy

2024-02-05 08:00 1223

* ACE2016 Is an Allogeneic Gamma Delta 2 (γδ2) T Cell Therapy Targeting the Epidermal Growth Factor Receptor (EGFR) in Patients With Solid Tumors. * Phase 1 Clinical Study Expected to Begin in H2 2024. ALAMEDA, Calif. and TAIPEI, Feb. 4, 2024 /PRNewswire/ -- Acepodia (6976:TT), a clinical stag...

Blossoming Flowers at the Top of the Biopharmaceutical Tree -- Reflections on the Flourishing of Sanyou's 4C Business

2024-02-03 08:00 2101

SHANGHAI, Feb. 2, 2024 /PRNewswire/ -- In 1996, MDS Pharma Service invested in and established the first true Contract Research Organization (CRO) inChina, dedicated to clinical trial business for new drugs. This marked the official launch of the CRO industry inChina. The concept of CRO originat...

Inmagene Exercises Option to Obtain Exclusive Worldwide License for IMG-007 and IMG-004 from HUTCHMED

2024-02-02 22:00 1492

* Inmagene exercised its option under the previously announced collaboration agreement to obtain an exclusive, royalty-bearing license for IMG-007, an anti-OX40 monoclonal antibody (mAb) and IMG-004, a Bruton Tyrosine Kinase (BTK) inhibitor * Inmagene retains rights to develop and commerciali...

World Cancer Day 2024: RemeGen Announces Three Significant Developments in the Global Fight Against Cancer, Narrowing the Care Gap

2024-02-02 21:30 1962

YANTAI, China, Feb. 2, 2024 /PRNewswire/ -- RemeGen Co. Ltd. ("RemeGen" or "the Company") (9995.HK, 688331.SH), a commercial-stage biotechnology company, with a mission that is closely aligned with the Close the Care Gap theme of World Cancer Day 2024 which falls on Febru...

1 ... 567891011 ... 148